Lilly and Incyte Announce Positive Top-Line Results From Phase 3 Trial of Baricitinib in Moderate to Severe Rheumatoid Arthritis
FIRST OF SEVERAL PHASE 3 TRIALS TO REPORT RESULTS
FERRING PHARMACEUTICALS TO ACQUIRE MARKETING RIGHTS FOR DDAVP® (DESMOPRESSIN) PRODUCT PORTFOLIO FROM SANOFI
Amgen Presents Data From Pivotal Phase 2 Study Of BLINCYTO™ (blinatumomab) Immunotherapy In Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
Secondary Analysis Demonstrates 40 Percent of Patients who Achieved Complete Remission Were Enabled to Proceed to Stem Cell Transplant
FDA Approves Amgen's XGEVA® (Denosumab) For The Treatment Of Hypercalcemia Of Malignancy Refractory To Bisphosphonate Therapy
Amgen And Onyx Announce Detailed Results From Phase 3 ASPIRE Study Of Kyprolis® (Carfilzomib) In Patients With Relapsed Multiple Myeloma
Data From Pivotal Trial Published in the New England Journal of Medicine and Presented at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition
Amgen Announces New Data From Phase 2 BLINCYTO™ (blinatumomab) Immunotherapy Study In Patients With Acute Lymphoblastic Leukemia And Minimal Residual Disease
78 Percent of Patients Treated With BLINCYTO Experienced a Complete Minimal Residual Disease (MRD) Response After One Treatment Cycle
Teva Receives Positive Outcome in Europe for Three-Times-a-Week COPAXONE® (Glatiramer Acetate) 40 mg/ml for the Treatment of Relapsing Forms of Multiple Sclerosis (RMS)
Study shows greatest cost linked to people with depression, COPD, coronary artery disease and dementia
ABBOTT PARK, Ill., Dec.
Mylan receives tentative FDA approval for paediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc.
Mylan receives tentative FDA approval for pediatric formulations of abacavir/lamivudine through innovative collaboration with ViiV Healthcare and Clinton Health Access Initiative
PITTSBURGH and LONDON, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc.